Cyclosporin ( DrugBank: Cyclosporin )

---

17 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
38	スティーヴンス・ジョンソン症候群	2
46	悪性関節リウマチ	3
49	全身性エリテマトーデス	4
50	皮膚筋炎／多発性筋炎	11
53	シェーグレン症候群	10
56	ベーチェット病	4
60	再生不良性貧血	64
62	発作性夜間ヘモグロビン尿症	3
63	特発性血小板減少性紫斑病	7
93	原発性胆汁性胆管炎	1
95	自己免疫性肝炎	2
97	潰瘍性大腸炎	16
113	筋ジストロフィー	1
164	眼皮膚白皮症	3
222	一次性ネフローゼ症候群	16
274	骨形成不全症	1
326	大理石骨病	1

38. スティーヴンス・ジョンソン症候群

---

臨床試験数 : 17 /  薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02987257 (ClinicalTrials.gov)	March 15, 2023	25/11/2016	NATIENS: Optimal Management and Mechanisms of SJS/TEN	NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses	Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3	Vanderbilt University Medical Center	University of Ottawa;University of Toronto	Not yet recruiting	18 Years	N/A	All	267	Phase 3	United States
2	NCT01488396 (ClinicalTrials.gov)	February 2007	8/11/2010	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye	Stevens-Johnson Syndrome	Drug: 0.05%cyclosporin eye drop	Mahidol University	NULL	Completed	18 Years	N/A	Both	31	Phase 4	Thailand

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00521924 (ClinicalTrials.gov)	June 2007	27/8/2007	Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)	Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-therapy	Rheumatoid Arthritis	Biological: infliximab;Drug: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.	Merck Sharp & Dohme Corp.	AESCA Pharma GmbH	Terminated	19 Years	65 Years	All	8	Phase 3	Austria
2	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States
3	NCT00209859 (ClinicalTrials.gov)	October 1998	16/9/2005	Methotrexate and Cyclosporine in Treatment of Early Rheumatoid Arthritis	Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Methotrexate;Drug: Intraarticular betamethasone;Drug: Cyclosporine/placebo-cyclosporine	Hvidovre University Hospital	NULL	Completed	18 Years	75 Years	Both	160	Phase 4	Denmark

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800019308	2018-11-12	2018-11-04	Efficacy and tolerability of multitarget therapy with NHMX for systemic lupus erythematosus	Efficacy and tolerability of multitarget therapy with NHMX for systemic lupus erythematosus	systemic lupus erythematosus	NHMX:One kind of non-steroid anti-inflammatory drugs combines with hydroxychloroquine sulfate(=200mg/bid) and methotrexate(7.5-20mg/w), with addition of glucocorticoid (=0.5mg/kg·d) or cyclosporine (maintaining the drug concentration between 30-90ug/l);control:hydroxychloroquine sulfate(=200mg/bid) and methotrexate(7.5-20mg/w), with addition of glucocorticoid (=0.5mg/kg·d) or cyclosporine(maintaining the drug concentration between 30-90ug/l);	The Third Affiliated Hospital, Southern Medical University	NULL	Recruiting	18	65	Both	NHMX:75;control:75;		China
2	NCT00976300 (ClinicalTrials.gov)	January 2002	11/9/2009	Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study	Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study	Systemic Lupus Erythematosus;Lupus Nephritis	Drug: Cyclosporine A;Drug: Cyclophosphamide	Institute of Rheumatology, Prague	Ministry of Health, Czech Republic;Charles University, Czech Republic;Palacky University;Department of Rheumatology, Hospital, Ceske Budejovice, Czech Republic;National Institute of Rheumatology, Piestany, Slovakia;Faculty Hospital St. Anna, Brno	Completed	18 Years	70 Years	Both	40	Phase 2	Czech Republic
3	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States
4	NCT00001212 (ClinicalTrials.gov)	November 1986	3/11/1999	Drug Therapy in Lupus Nephropathy	Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy	Nephrotic Syndrome;Systemic Lupus Erythematosus	Drug: prednisone;Drug: cyclophosphamide;Drug: cyclosporin A	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Completed	N/A	N/A	Both	45	Phase 2	United States

50. 皮膚筋炎／多発性筋炎

---

臨床試験数 : 194 /  薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000036709	2020-10-01	2020-08-24	Study on early warning of rapid progressive interstitial lung disease in dermatomyositis	Study on early warning of rapid progressive interstitial lung disease in dermatomyositis	Dermatomyositis	Group 1:Glucocorticoid + cyclophosphamide + cyclosporin;Group 2:Glucocorticoid + cyclophosphamide + Tofacitinib;	Zhongshan Hospital of Fudan University	NULL	Pending	18	60	Both	Group 1:15;Group 2:15;	N/A	China
2	ChiCTR1900025087	2019-09-01	2019-08-10	Cyclosporine A in the treatment of polymyositis /dermatomyositis associated interstitial pulmonary disease: a prospective, opened, multicenter, randomized, controlled clinical study	Cyclosporine A in the Treatment of Polymyositis /Dermatomyositis With Interstitial Lung Disease (CTP /DMILD): a Prospective, Opened, Randomized, Multicenter, Controlled Trial	Polymyositis/Dermatomyositis associated Interstitial Lung Disease	treatment group:CsA+glucocorticoid;control group:CTX+glucocorticoid;	Guangdong Provincial People's Hospital	NULL	Pending			Both	treatment group:75;control group:75;	Phase 4	China
3	JPRN-UMIN000015469	2014/10/20	18/10/2014	Comparison of efficacy between tacrolimus and cyclosporine for the treatment of polymyositis/dermatomyositis-associated interstitial lung disease	Comparison of efficacy between tacrolimus and cyclosporine for the treatment of polymyositis/dermatomyositis-associated interstitial lung disease - Comparison between tacrolimus and cyclosporine for the treatment of PM/DM-ILD	polymyositis/dermatomyositis/clinically amyopathic dermatomyositis-associated Interstitial lung disease	arm1: tacrolimus and predonisolon therapy for 52 weeks Initial dose of oral prednisolone is 0.6 - 1 mg/kg/day. Intravenous methylprednisolone pulse therapy (1 g/day for 3 days) is permitted according to the disease activity. After 4 weeks of initial treatment, prednisolone was tapered by approximately 10 to 20% every 2 to 4 weeks and continued at dose of 0.125 mg/kg/day or more. Taclorimus is administered orally at initial dose of 0.075 mg/kg/day (twice daily) and adjusted over time to maintain a whole-blood trough level of 5 - 10 ng/ml. arm2: cyclosporine and predonisolone therapy for 52 weeks Initial dose of oral prednisolone is 0.6 - 1 mg/kg/day. Intravenous methylprednisolone pulse therapy (1 g/day for 3 days) is permitted according to the disease activity. After 4 weeks of initial treatment, prednisolone was tapered by approximately 10 to 20% every 2 to 4 weeks and continued at dose of 0.125 mg/kg/day or more. Cyclosporine is administered orally at initial dose of 3 mg/kg/day (twice daily before meal) and adjusted over time to maintain a whole-blood trough level of 100 - 150 ng/ml.	Second Division, Department of Internal medicine, Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	18years-old	75years-old	Male and Female	50	Not selected	Japan
4	JPRN-UMIN000001866	2009/04/01	10/04/2009	Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis	Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis - Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis	Dermatomyositis or polymyositis with interstitial pneumonia	(1)The patients are initially treated with methylprednisolone (m-PSL) pulse (1000 mg daily for three days) followed by oral prednisolone (1mg/kg daily). (2)Continuous intravenous CyA (2 mg/kg daily for initial dose) is started following m-PSL pulse therapy, and the dosage will be adjusted to a level of 200-300ng/ml.	Department of Neurology and Rheumatology, Shinshu University School of Medicine	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	10	Not selected	Japan
5	EUCTR2005-003956-37-GB (EUCTR)	18/06/2008	20/03/2008	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisolone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisolone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Juvenile Dermatomyositis at onset	Trade Name: treatment defined only by active substance Product Name: prednisone Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methylprednisolone Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methotrexate Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methotrexate Product Code: not available INN or Proposed INN: not availa	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
6	EUCTR2005-003956-37-SE (EUCTR)	23/02/2007	11/12/2006	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Juvenile Dermatomyositis at onset	Trade Name: treatment defined only by active substance Product Name: Prednisone Product Code: Not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methylprednisolone Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: Cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: not available Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: Cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: Methotrexate Product Code: not available	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
7	EUCTR2005-003956-37-BE (EUCTR)	13/11/2006	25/10/2006	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate - PRINTO JDM Trial	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate - PRINTO JDM Trial	Juvenile Dermatomyositis at onset	Product Name: Prednisolone INN or Proposed INN: Methylprednisolone Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolone sodium succinate Product Name: Cyclosporine INN or Proposed INN: Cyclosporine A Product Name: Cyclosporine INN or Proposed INN: Cyclosporine A Product Name: Methotrexate INN or Proposed INN: Methotrexate Product Name: Methotrexate INN or Proposed INN: Methotrexate	University Hospital Gent	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
8	EUCTR2005-003956-37-DK (EUCTR)	03/11/2006	15/09/2006	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Juvenile Dermatomyositis at onset	Product Name: Prednisone Product Name: methylprednisolone Product Name: Cyclosporine Product Name: Cyclosporine Product Name: Cyclosporine Product Name: Metotrexate Product Name: Methotrexate	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	Belgium;Denmark;Netherlands;United Kingdom;Italy;Sweden
9	EUCTR2005-003956-37-NL (EUCTR)	26/09/2006	01/06/2006	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis:prednisone versus prednisone plus cyclosporine A versus prednisone plus mehotrexate	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis:prednisone versus prednisone plus cyclosporine A versus prednisone plus mehotrexate	Juvenile Dermatomyositis at onset	INN or Proposed INN: Prednisone INN or Proposed INN: Methylprednisolone INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Methotrexate INN or Proposed INN: Methotrexate	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	160	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
10	EUCTR2005-003956-37-IT (EUCTR)	02/05/2006	12/09/2006	FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE PLUS METHOTREXATE - ND	FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE PLUS METHOTREXATE - ND	New Onset juvenile dermatomyositis MedDRA version: 6.1;Level: PT;Classification code 10012503	INN or Proposed INN: Prednisone INN or Proposed INN: Methylprednisolone INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Methotrexate INN or Proposed INN: Methotrexate	ISTITUTO GIANNINA GASLINI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
11	NCT00323960 (ClinicalTrials.gov)	May 2006	9/5/2006	Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis	Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate	Juvenile Dermatomyositis	Drug: 3 MPDN pulse + PDN;Drug: 3 MPDN pulse + PDN + CSA;Drug: 3 MPDN pulse + PDN + MTX	Istituto Giannina Gaslini	Pediatric Rheumatology International Trials Organization	Recruiting	1 Year	18 Years	Both	120	Phase 3	Italy

先頭へ

53. シェーグレン症候群

---

臨床試験数 : 305 /  薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003749-39-IT (EUCTR)	15/12/2021	15/10/2021	A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A.	A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. - NGF0221	Severe Sjogren’s dry eye disease MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Trade Name: Oxervate Product Name: OXERVATE Product Code: [Recombinant Human Nerve Growth Factor (rhNGF)] INN or Proposed INN: Cenegermin Other descriptive name: Recombinant form of human nerve growth factor produced in Escherichia Coli.	DOMPé FARMACEUTICI S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Phase 3	United States;Italy
2	NCT04835623 (ClinicalTrials.gov)	June 21, 2021	5/4/2021	CEQUA for Sjogren's Syndrome Dry Eye	Effects of CEQUA™ on Objective and Subjective Dry Eye Findings Associated With Sjogren's Syndrome	Dry Eye;Dry Eye Syndromes;Sjogren's Syndrome	Drug: Cyclosporine 0.09% Ophthalmic Solution	Center for Ophthalmic and Vision Research, LLC	Sun Pharmaceutical Industries Limited	Recruiting	18 Years	70 Years	All	50	Phase 4	United States
3	NCT04597762 (ClinicalTrials.gov)	August 31, 2020	16/10/2020	Effect of Ciclosporin Eyedrops on Sjögren Syndrome	Effect of Ciclosporin Eyedrops on Ocular Symptoms and Optical Quality in Patients With Sjögren Syndrome	Dry Eye Syndromes	Drug: Cyclosporin;Drug: Hydrocortisone	Hospital Hietzing	NULL	Completed	18 Years	90 Years	All	12	N/A	Austria
4	NCT03865888 (ClinicalTrials.gov)	October 30, 2018	16/12/2018	Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome	Evaluation of the Effect of Topical Application of Tacrolimus 0.03% (FK506) Eye Drops Versus Cyclosporine 0.05% Eye Drops in Treatment of Dry Eye in Secondary Sjogren Syndrome	Dry Eye;Sjogren Syndrome	Drug: Cyclosporins;Drug: Tacrolimus	Pavly Moawd	NULL	Completed	20 Years	70 Years	All	60	Phase 3	Egypt
5	ChiCTR-IPR-15005990	2015-03-23	2015-02-10	Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Cyclosporine A in the Treatment of Interstitial Pneumonitis associated with Sjogren’s syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Sjogren's syndrome	Treatment group:glucocorticoid+CsA;Control group:glucocorticoid+placebo;	Peking University People's Hospital	NULL	Pending	18	75	Both	Treatment group:120;Control group:120;		China
6	NCT02370550 (ClinicalTrials.gov)	March 2015	18/2/2015	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome	Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial	Sjogren's Syndrome	Drug: Cyclosporin A;Drug: Prednisone;Drug: Placebo;Drug: Calcium carbonate D	Peking University People's Hospital	NULL	Recruiting	18 Years	75 Years	All	240	Phase 4	China
7	NCT02004067 (ClinicalTrials.gov)	January 2013	3/12/2013	Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Primary Sjogren Syndrome;Secondary Sjogren Syndrome;Aqueous Deficient Dry Eye Disease;Evaporative Dry Eye Disease	Drug: Restasis;Drug: Refresh Endura	Federal University of São Paulo	Allergan	Completed	18 Years	65 Years	All	100	Phase 4	Brazil
8	NCT01693393 (ClinicalTrials.gov)	March 2010	14/9/2012	Low Dose Cyclosporin A in Primary Sjögren Syndrome	A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome	Sjögren´s Syndrome	Drug: Cyclosporine A	Charite University, Berlin, Germany	NULL	Completed	18 Years	75 Years	Both	30	Phase 2	Germany
9	NCT00001731 (ClinicalTrials.gov)	November 1997	3/11/1999	Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops	A Double-Masked, Randomized, Vehicle-Controlled Pilot Study of the Treatment of Keratoconjunctivitis Sicca With Topical Cyclosporin A 0.1% Emulsion	Keratoconjunctivitis Sicca;Sjogren's Syndrome	Drug: Cyclosporin A	National Eye Institute (NEI)	NULL	Completed	N/A	N/A	Both	30	Phase 2	United States
10	EUCTR2009-013976-38-DE (EUCTR)		07/12/2009	Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress	Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) - Cypress	Primary Sjögren's Syndrome MedDRA version: 12.1;Level: LLT;Classification code 10059142;Term: Sjoegren's syndrome	Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral INN or Proposed INN: CICLOSPORIN	Charité Berlin, Department of rheumatology	Charité Berlin, department of rheumatology;Charité Berlin, department of rheumatology	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Germany

先頭へ

56. ベーチェット病

---

臨床試験数 : 81 /  薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000031637	2020-04-10	1990-01-01	Behcet’s Uveitis Therapy (BUT) Study	Behcet’s Uveitis Therapy (BUT) Study	Uveitis in Behcet’s Disease	Arm A: Interferon Alpha-2a;Arm B:Adalimumab;Arm C:Cyclosporine;	The First Affiliated Hospital of Chongqing Medical University	NULL	Pending			Both	Arm A:90;Arm B:90;Arm C:90;	Phase 4	China
2	NCT03209219 (ClinicalTrials.gov)	June 30, 2017	4/7/2017	Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis	Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis	Behçet Disease;Uveitis	Drug: Interferon Alfa-2A;Drug: Cyclosporine Pill	Peking Union Medical College Hospital	NULL	Completed	18 Years	65 Years	All	28	Phase 3	China
3	JPRN-UMIN000025451	2017/04/01	28/12/2016	Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease	Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease	refractory uveitis of Behcet's disease	Patients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.	Yokohama City University Hospital	NULL	Complete: follow-up complete	20years-old	65years-old	Male and Female	5	Not selected	Japan
4	NCT00167583 (ClinicalTrials.gov)	November 2004	9/9/2005	Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)	Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)	Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal Vasculitis	Drug: Cyclosporin A;Drug: Interferon-alpha2a	University Hospital Tuebingen	NULL	Completed	18 Years	75 Years	All	37	Phase 3	Germany

60. 再生不良性貧血

---

臨床試験数 : 245 /  薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05323617 (ClinicalTrials.gov)	May 15, 2023	5/4/2022	Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy	Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Adult Severe Aplastic Anemia Participants Who Are Either Previously Untreated With IST or Refractory to IST	Severe Aplastic Anemia (SAA)	Drug: Romiplostim;Drug: Antithymocyte Globulin;Drug: Cyclosporine A	Amgen	NULL	Not yet recruiting	18 Years	N/A	All	40	Phase 2	NULL
2	NCT05600426 (ClinicalTrials.gov)	January 25, 2023	20/10/2022	A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)	A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)	Severe Aplastic Anemia	Drug: cyclosporine;Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant;Drug: horse anti-thymocyte globulin (ATG);Drug: rabbit anti-thymocyte globulin (ATG);Drug: Methotrexate;Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: low-dose total body irradiation (TBI);Procedure: Immunosuppressive Therapy (IST)	Boston Children's Hospital	Center for International Blood and Marrow Transplant Research;National Institutes of Health (NIH);National Heart, Lung, and Blood Institute (NHLBI);North American Pediatric Aplastic Anemia Consortium;Pediatric Transplantation and Cellular Therapy Consortium;Blood and Marrow Transplant Clinical Trials Network	Recruiting	0 Years	25 Years	All	234	Phase 3	United States
3	ChiCTR2200056659	2023-01-16	2022-02-10	Allopurinol in the treatment of cyclosporine-induced hyperuricemia in children with aplastic anemia:a randomized controlled study	Allopurinol in the treatment of cyclosporine-induced hyperuricemia in children with aplastic anemia:a randomized controlled study	hyperuricemia	Allopurinol group:Receive allopurinol tablets;Placebo group:Receive placebo;	The Seventh Affiliated Hospital, Sun Yat-sen University	NULL	Pending	1	18	Both	Allopurinol group:20;Placebo group:20;	Phase 4	China
4	NCT05660785 (ClinicalTrials.gov)	December 1, 2022	23/11/2022	Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia	The Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic Anemia	Non Severe Aplastic Anemia;Untreated	Drug: Herombopag	Institute of Hematology & Blood Diseases Hospital	Jiangsu Hengrui Pharmaceuticals Co.,Ltd	Recruiting	18 Years	N/A	All	54	Phase 2	China
5	NCT05049668 (ClinicalTrials.gov)	October 2021	13/9/2021	RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial	Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients	Severe Aplastic Anemia	Drug: ATGAM plus CsA with or without Eltrombopag	European Society for Blood and Marrow Transplantation	NULL	Enrolling by invitation	N/A	N/A	All	197		France
6	ChiCTR2100050948	2021-09-10	2021-09-08	Comparison of clinical efficacy and safety of hematopoietic stem cell transplantation and immunosuppression in the treatment of hepatitis-related aplastic anemia: a single-center cohort study	Comparison of clinical efficacy and safety of hematopoietic stem cell transplantation and immunosuppressive therapy in patients with hepatitis-related aplastic anemia	Hepatitis-associated Aplastic Anemia	ematopoietic stem cell transplantation group:Nil;ATG combined with cyclosporine group :Nil;	Zhejiang Provincial Hospital of Traditional Chinese Medicine	NULL	Recruiting	1	50	Both	ematopoietic stem cell transplantation group:30;ATG combined with cyclosporine group :30;		China
7	ChiCTR2100043229	2021-02-22	2021-02-09	A Single-Center, Single-Arm, Phase II Clinical Study of the Efficacy and Safety of Cyclosporine Combined with Eltrombopag Olamine Tablets in Treatment-Naive Transfusion-Dependent Non-Severe Aplastic Anemia	A Single-Center, Single-Arm, Phase II Clinical Study of the Efficacy and Safety of Cyclosporine Combined with Eltrombopag Olamine Tablets in Treatment-Naive Transfusion-Dependent Non-Severe Aplastic Anemia	Aplastic anemia	Durgs Group:Elrombopag combined with Cyclosporine;	Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences	NULL	Recruiting	18	85	Both	Durgs Group:61;	Phase 2	China
8	ChiCTR2000041485	2021-01-01	2020-12-27	Efficacy of Danazol after no response to cyclosporin in transfusion independent aplastic anemia: a prospective study	Efficacy of Danazol after no response to cyclosporin in transfusion independent aplastic anemia: a prospective study	transfusion independent aplastic anemia	experimental group:Cyclosporine combined with danazol;control group:Cyclosporine;	Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College	NULL	Recruiting			Both	experimental group:152;control group:76;	Phase 4	China
9	NCT04328727 (ClinicalTrials.gov)	November 4, 2020	9/3/2020	Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia	A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine A (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS)	Severe Aplastic Anemia (SAA)	Drug: eltrombopag;Drug: rabbit anti-thymocyte globulin (r-ATG);Drug: cyclosporine A (CsA)	Novartis Pharmaceuticals	NULL	Active, not recruiting	6 Years	N/A	All	36	Phase 2	China;Japan;Korea, Republic of;Taiwan
10	NCT04304820 (ClinicalTrials.gov)	May 7, 2020	10/3/2020	Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)	Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)	Severe Aplastic Anemia	Drug: Eltrombopag;Drug: Cyclosporine;Drug: Horse-Anti-thymocyte-Globulin	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Recruiting	3 Years	N/A	All	39	Phase 2	United States
11	ChiCTR1900027553	2019-11-28	2019-11-18	Clinical therapies for patients in subtypes of non-severe aplastic anemia	Clinical therapies for patients in subtypes of non-severe aplastic anemia	non-severe aplastic anemia	early NSAA:Cyclosporine;moderate NSAA1:Cyclosporine;moderate NSAA2:Cyclosporine+Danazol;TD NSAA:CSA+TPO+G-CSF;	Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences	NULL	Pending	18	85	Both	early NSAA:89;moderate NSAA1:37;moderate NSAA2:39;TD NSAA:325;		China
12	JPRN-jRCTs071190032	26/11/2019	21/10/2019	W-JHS AA02	Investigation on the effectiveness of rabbit ATG + cyclosporine + eltrombopag therapy for patients with aplastic anemia - W-JHS AA02	aplastic anemia	1. The administration of rATG; 2.5 mg/kg, iv. daily, day 1 - day 5 + CsA; 5 mg/kg, po. bid (before breakfast and before dinner) +adrenalcorticosteroid (the dose is mentioned after) is started. CsA used is Neoral or generic drug emulsified in the same way with Neoral. A blood level of CsA is measured and the dose which CsA blood level 2 hours after oral administration (C2) reachs 600 - 900 ng/mL is adjusted. The investigator shall reduce the dose of CsA by 25% on this occasion when blood trough level (C0) just before the administration is beyond 250 ng/mL because renal function disorder may occur (2). When serum creatinine level also becomes higher than 150% of baselines, the 25% dose reduction of CsA shall be performed. If C2 did not reach to 600 ng/mL, then dose of CsA is appropriately increased. 2. EPAG; 75 mg, po. daily (before sleep, requires to pass more than at least 2 hours after dinner) is started from day 6. 3. The dose of steroid is as follows: Day 1 - day 5: methylprednisolone 2 mg/kg/day Day 6: Methylprednisolone 1 mg/kg/day Day 8, 10, 12, 14, 16, 18, 20: prednisolone 0.5 mg/kg/day Discontinuation after day 21 4. The administration of CsA and EPAG is continued for 26 weeks. When it passed 26 weeks, further treatment mentioned above is entrusted to the investigator in each medical institution after 27 weeks if patients reached Camitta criteria CR or PR. However, the administration is continued for 52 weeks even if the dose of CsA is reduced. The treatment after 53 weeks is not specified. If patients did not reach CR or PR at 26 weeks, treatment after 27 weeks is entrusted to the investigator in each medical institution (it is not specified in this study).	Ishiyama Ken	NULL	Recruiting	>= 18age old	< 80age old	Both	60	Phase 2	Japan
13	NCT03896971 (ClinicalTrials.gov)	November 15, 2019	21/3/2019	Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia	Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia	Aplastic Anemia	Drug: Combination of thrombopoietin mimetic and cyclosporin A	Safaa AA Khaled	Assiut University	Completed	16 Years	65 Years	All	66	Phase 4	Egypt
14	EUCTR2016-002814-29-IT (EUCTR)	14/06/2019	24/05/2021	SOAR, Interventional phase II single-arm study to assess efficacy and safety of eltrombopag combined with cyclosporine as first line therapy in adult patients with severe acquired aplastic anemia	SOAR, Interventional phase II single-arm study to assess efficacy and safety of eltrombopag combined with cyclosporine as first line therapy in adult patients with severe acquired aplastic anemia - SOAR	First-line severe aplastic anaemia MedDRA version: 20.0;Level: PT;Classification code 10002967;Term: Aplastic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE Product Name: Sandimmun Neoral Product Code: [Sandimmun Neoral ] INN or Proposed INN: 00070500 Other descriptive name: CICLOSPORINA Trade Name: SANDIMMUN NEORAL - 25 MG CAPSULE MOLLI 50 CAPSULE Product Name: Sandimmun Neoral Product Code: [Sandimmun Neoral] INN or Proposed INN: 00070500 Other descriptive name: CICLOSPORINA Trade Name: SANDIMMUN NEORAL - 50 MG CAPSULE MOLLI 50 CAPSULE Product Name: Sandimmun Neoral Product Code: [Sandimmun Neoral] INN or Proposed INN: 00070500 Trade Name: SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE Product Name: Sandimmun Neoral Product Code: [Sandimmun Neoral] INN or Proposed INN: 00070500 Trade Name: REVOLADE - 25 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER(PA/ALU/PVC/ALU) 28 COMPRESSE Product Name: Eltrombopag Product Code: [ETB115] INN or Proposed INN: 00319301 Other descriptive name: Eltrombopag Trade Name: REVOLADE - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER(PA/ALU/PVC/ALU	NOVARTIS PHARMA AG	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Hungary;Hong Kong;Mexico;Spain;Thailand;Brazil;Korea, Democratic People's Republic of;Turkey;Netherlands;Italy;India
15	NCT03218657 (ClinicalTrials.gov)	January 1, 2018	16/6/2017	Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole	A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride	Aplastic Anemia	Drug: levamisole hydrochloride;Drug: Androgens;Drug: Cyclosporins	Shengyun Lin	NULL	Recruiting	18 Years	70 Years	All	248	N/A	China
16	JPRN-UMIN000030453	2017/12/20	18/12/2017	Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia	Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia - Aplastic anemia 01 study in West Japan Hematology Study Group (W-JHS AA01 study)	aplastic anemia	1.Start CsA (Neoral or generic drugs emulsified in the same way as Neoral) at a dose of 3.5 mg/kg, bid (before breakfast and before dinner). 2.Measure the blood concentration of cyclosporine at 2 hours (C2) after taking the drug and determine the minimum dose of cyclosporine that produces C2 >600 ng/mL. Continue the dose of cyclosporine for 8 weeks. 3.Continue the treatment for further 44 weeks (a total of 52 weeks) when patients meet the response criteria of HI-E or HI-P at the end of the 8 week treatment. Treatments after the 52 weeks are not specified. When patients do not meet the IWG response criteria 2006 at the end of 8 weeks, the treatment is terminated and treatments after 9 weeks are not specified.	Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu	NULL	Complete: follow-up continuing	16years-old	Not applicable	Male and Female	33	Not selected	Japan
17	NCT03243656 (ClinicalTrials.gov)	December 20, 2017	2/8/2017	Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia	Randomized Clinical Trial of the Use of & Cyclosporine in Children With Sever Idiopathic Aplastic Anemia	Eltrombopag	Drug: Eltrombopag	Assiut University	NULL	Completed	1 Year	18 Years	All	20	Phase 4	Egypt
18	EUCTR2016-002814-29-HU (EUCTR)	07/09/2017	05/07/2017	SOAR Trial: Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired aplastic anemia with follow-up up to 60-months.	SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired aplastic anemia, and an extension with up to 60-months follow-up. - SOAR	First-line severe aplastic anaemia MedDRA version: 20.0;Level: PT;Classification code 10002967;Term: Aplastic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 INN or Proposed INN: ELTROMBOPAG	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	France;Hong Kong;Hungary;Mexico;Spain;Brazil;Turkey;Netherlands;Italy;Korea, Republic of;India
19	EUCTR2016-002814-29-NL (EUCTR)	21/07/2017	29/03/2017	SOAR Trial: Eltrombopag combined with cyclosporine as first line therapy in adult patients with severe acquired aplastic anemia with follow-up up to 24-months.	SOAR, Interventional phase II single-arm study to assess efficacy and safety of eltrombopag combined with cyclosporine as first line therapy in adult patients with severe acquired aplastic anemia - SOAR	First-line severe aplastic anaemia MedDRA version: 20.0;Level: PT;Classification code 10002967;Term: Aplastic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 INN or Proposed INN: ELTROMBOPAG	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Hungary;Hong Kong;Mexico;Thailand;Spain;Brazil;Turkey;Netherlands;Italy;Korea, Republic of;India
20	ChiCTR-IOR-17011653	2017-07-01	2017-06-14	A prospective, randomized, controlled clinical study of non transfusion dependent non severe aplastic anemia treated with cyclosporine, androgen and levamisole hydrochloride	A prospective, randomized, controlled clinical study of non transfusion dependent non severe aplastic anemia treated with cyclosporine, androgen and levamisole hydrochloride	Aplastic anemia	SA group:none;LSA group:levamisole hydrochloride;	The First affiliated Hospital of Zhejiang Chinese Medical University	NULL	Pending	18	70	Both	SA group:124;LSA group:124;		China
21	EUCTR2016-002814-29-ES (EUCTR)	21/03/2017	16/12/2016	SOAR Trial: Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired aplastic anemia with follow-up up to 60-months.	SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired aplastic anemia, and an extension with up to 60-months follow-up. - SOAR	First-line severe aplastic anaemia MedDRA version: 19.0;Level: PT;Classification code 10002967;Term: Aplastic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 INN or Proposed INN: ELTROMBOPAG Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 INN or Proposed INN: ELTROMBOPAG	Novartis Farmacéutica, S.A	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	Qatar;Hong Kong;Spain;Turkey;Italy;India;France;Hungary;Mexico;Canada;Brazil;Netherlands;Korea, Republic of
22	NCT03413306 (ClinicalTrials.gov)	December 10, 2016	22/12/2017	Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA	A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATG Versus hATG and CsA as First Line Treatment in Pediatric Patients With Severe Acquired Aplastic Anemia	Acquired Aplastic Anemia	Drug: Eltrombopag;Drug: IST (ATG + CsA)	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	NULL	Recruiting	2 Years	18 Years	All	100	Phase 3	Russian Federation
23	ChiCTR-IOR-16008738	2016-08-01	2016-06-28	A single center, randomized, controlled, opened label study for evaluating Cyclosporin alone or combined with Stanozolol in the treatment of aplastic anemia	A single center, randomized, controlled, opened label study for evaluating Cyclosporin alone or combined with Stanozolol in the treatment of aplastic anemia	aplastic anemia	A:Cyclosporin;B:Cyclosporin and Stanozolol;	The First Affiliated Hospital of Zhengzhou University	NULL	Recruiting	18	65	Both	A:100;B:100;		China
24	NCT02845596 (ClinicalTrials.gov)	August 2016	9/5/2016	Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia	Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: cyclosporine;Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;Drug: horse anti-thymocyte globulin (ATG);Drug: rabbit anti-thymocyte globulin (ATG);Drug: methotrexate;Drug: fludarabine;Drug: cyclophosphamide;Radiation: low-dose total body irradiation (TBI);Procedure: Immunosuppressive Therapy (IST)	Michael Pulsipher, MD	NULL	Active, not recruiting	N/A	25 Years	All	40	N/A	United States
25	EUCTR2014-000363-40-NL (EUCTR)	07/01/2016	01/09/2015	A trial in which will be studied if the addition of a medicine that is used for improving platelet counts (eltrombopag) to the regular treatment for aplastic anemia (hATG + CsA) also improves the numbers of other cell lines and therefore the overall bone marrow function.	A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients. - RACE	Idiopathic (Severe) Aplastic Anemia, a bone marrow failure syndrome which results in the normal hematopoietic tissue completely missing from the bone marrow, accounting for the subsequent pancytopenia. MedDRA version: 19.0;Level: PT;Classification code 10002967;Term: Aplastic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: REVOLADE INN or Proposed INN: ELTROMBOPAG	European Society for Blood and Marrow Transplantation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 3	Spain;Netherlands
26	NCT02745717 (ClinicalTrials.gov)	January 2016	7/4/2016	The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia	The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: Thymoglobulin;Procedure: Cord blood;Drug: Cyclosporine Oral Product	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Ruijin Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai Tongji Hospital, Tongji University School of Medicine;Zhejiang Provincial Hospital of TCM	Completed	N/A	60 Years	All	60	Phase 4	China
27	EUCTR2014-000363-40-ES (EUCTR)	26/10/2015	07/09/2015	A trial in which will be studied if the addition of a medicine that is used for improving platelet counts (eltrombopag) to the regular treatment for aplastic anemia (hATG + CsA) also improves the numbers of other cell lines and therefore the overall bone marrow function.	A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients. - RACE	Idiopathic (Severe) Aplastic Anemia, a bone marrow failure syndrome which results in the normal hematopoietic tissue completely missing from the bone marrow, accounting for the subsequent pancytopenia. MedDRA version: 18.0;Level: PT;Classification code 10002967;Term: Aplastic anaemia;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Trade Name: Revolade INN or Proposed INN: ELTROMBOPAG	European Society for Blood and Marrow Transplantation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200		Spain
28	NCT02462252 (ClinicalTrials.gov)	October 2015	25/5/2015	Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)	Aplastic Anemia;Hypoplastic Myelodysplastic Syndrome	Drug: BL-8040;Drug: horse anti-thymocyte globulin (hATG);Drug: Methylprednisolone;Drug: Cyclosporine	BioLineRx, Ltd.	NULL	Recruiting	18 Years	N/A	All	25	Phase 2	United States
29	ChiCTR1900028153	2015-07-01	2019-12-13	A Multi-centre Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia	A Multi-centrer Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia	Aplstic Anemia	Experimental group:Pai-Neng-Da Capsule + Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D);Control group:Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D);	Jinhua people's Hospital	NULL	Completed			Both	Experimental group:50;Control group:50;	Phase 2-3	NULL
30	ITMCTR1900002832	2015-07-01	2019-12-13	A Multi-centre Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia	A Multi-centrer Clinical Study of Pai-Neng-Da Capsule in the Treatment of Chronic Aplastic Anemia	Aplstic Anemia	Control group:Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D);Experimental group:Pai-Neng-Da Capsule + Testosterone undecanoate capsule (80mg / day), cyclosporine capsule (3-7mg / kg. D);	Jinhua people's Hospital	NULL	Completed			Both	Control group:50;Experimental group:50;		NULL
31	NCT02099747 (ClinicalTrials.gov)	July 2015	6/3/2014	hATG+CsA vs hATG+CsA+Eltrombopag for SAA	A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.	Severe Aplastic Anemia	Drug: hATG;Drug: CsA;Drug: Eltrombopag	European Group for Blood and Marrow Transplantation	Novartis;Pfizer	Active, not recruiting	15 Years	N/A	All	202	Phase 3	France;Italy;Netherlands;Spain;Switzerland;United Kingdom;Germany
32	NCT02404025 (ClinicalTrials.gov)	May 12, 2015	26/2/2015	Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects	A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy	Aplastic Anemia	Drug: Eltrombopag;Drug: Rabbit ATG;Drug: CsA	Novartis Pharmaceuticals	NULL	Completed	18 Years	75 Years	All	10	Phase 2	Japan
33	NCT02203396 (ClinicalTrials.gov)	August 2014	27/7/2014	A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia	A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia	Aplastic Anemia	Drug: rabbit ATG, Cyclosporine, Levamisole	Yizhou Zheng	NULL	Recruiting	6 Years	70 Years	Both	40	Phase 2	China
34	NCT02028416 (ClinicalTrials.gov)	September 2013	2/1/2014	Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia	Protocol for Comparison of Two Different Regimens of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia	Aplastic Anemia	Drug: ATG-fresenius	National Institute of Blood Disease Center, Pakistan	NULL	Recruiting	2 Years	65 Years	Both	60	N/A	Pakistan
35	NCT01760096 (ClinicalTrials.gov)	January 2013	1/1/2013	Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Paroxysmal Nocturnal Hemoglobinuria;Hemoglobinuria;Hemoglobinuria, Paroxysmal;Proteinuria;Urination Disorders;Thrombosis;Bone Marrow Failure;Aplastic Anemia,;Anemia, Hemolytic	Drug: Levamisole+cyclosporin A+Glucocorticoids;Drug: cyclosporin A+Glucocorticoids;Drug: Glucocorticoids	Institute of Hematology & Blood Diseases Hospital	NULL	Active, not recruiting	18 Years	N/A	Both	50	Phase 2	China
36	NCT01659606 (ClinicalTrials.gov)	July 2012	6/8/2012	Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita	Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease	Dyskeratosis Congenita;Hoyeraal Hreidarsson Syndrome;Revesz Syndrome;Aplastic Anemia	Biological: alemtuzumab;Drug: Fludarabine;Drug: Cyclosporins;Drug: Mycophenolate mofetil;Drug: Tacrolimus	Boston Children's Hospital	Dana-Farber Cancer Institute;Children's Hospital Medical Center, Cincinnati;Children's Hospital Los Angeles;Fred Hutch/University of Washington/Seattle Children's Cancer Consortium;Baylor College of Medicine;Children's Hospital of Philadelphia;University of Wisconsin, Madison;Karolinska University Hospital;Hackensack Meridian Health;Duke University;Oslo University Hospital;Children's Mercy Hospital Kansas City;Mayo Clinic;University of Chicago;Massachusetts General Hospital	Active, not recruiting	30 Days	65 Years	All	40	Phase 2	United States;Norway;Sweden
37	NCT01642979 (ClinicalTrials.gov)	July 2012	14/7/2012	Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Paroxysmal Nocturnal Hemoglobinuria;Hemoglobinuria;Hemoglobinuria, Paroxysmal;Proteinuria;Urination Disorders;Thrombosis;Bone Marrow Failure;Aplastic Anemia,;Anemia, Hemolytic	Drug: Levamisole+cyclosporin A+Glucocorticoids;Drug: cyclosporin A+Glucocorticoids;Drug: Glucocorticoids	Institute of Hematology & Blood Diseases Hospital	NULL	Active, not recruiting	18 Years	N/A	Both	120	Phase 2	China
38	NCT01624805 (ClinicalTrials.gov)	June 25, 2012	19/6/2012	Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome	Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)	Aplastic Anemia;de Novo Myelodysplastic Syndrome;Myelodysplastic Syndrome;Previously Treated Myelodysplastic Syndrome	Biological: Anti-Thymocyte Globulin;Drug: Cyclosporine;Biological: Filgrastim;Drug: Methylprednisolone;Biological: Pegfilgrastim	M.D. Anderson Cancer Center	National Cancer Institute (NCI)	Recruiting	N/A	N/A	All	100	Phase 2	United States
39	NCT01995331 (ClinicalTrials.gov)	March 2012	21/11/2013	Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia	Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia	Aplastic Anemia	Drug: cyclophosphamide,cyclosporine A	Xiaofan Zhu	NULL	Active, not recruiting	1 Year	18 Years	Both	30	Phase 4	China
40	NCT01193283 (ClinicalTrials.gov)	August 2010	31/8/2010	Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia	Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia	Aplastic Anemia;Neutropenia;Pancytopenia;Severe Aplastic Anemia	Drug: Cyclophosphamide;Drug: Cyclosporine	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	N/A	All	22	Phase 1/Phase 2	United States
41	NCT00987480 (ClinicalTrials.gov)	September 25, 2009	30/9/2009	Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine	Aplastic Anemia;Leukemia;Myelodysplastic Syndrome	Drug: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.;Device: CliniMACS device	Memorial Sloan Kettering Cancer Center	Boston Children's Hospital;Children's Hospital Medical Center, Cincinnati;Children's Hospital and Health System Foundation, Wisconsin;Rockefeller University;Fred Hutchinson Cancer Research Center	Completed	N/A	N/A	All	45	Phase 2	United States
42	NCT00944749 (ClinicalTrials.gov)	July 2009	22/7/2009	Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment	Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment	Anemia, Aplastic;Anemia, Hypoplastic	Drug: h-ATG (ATGAM );Drug: Cyclosporine (Gengraf )	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	82 Years	All	23	Phase 2	United States
43	EUCTR2009-012746-23-IT (EUCTR)	12/05/2009	24/06/2009	pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept - ND	pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept - ND	acquired aplastic anemia MedDRA version: 9.1;Level: SOC;Classification code 10005329	Trade Name: ENBREL*SC 4FL 25MG+4SIR 1ML INN or Proposed INN: Etanercept	ISTITUTO GIANNINA GASLINI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
44	EUCTR2007-000902-55-FR (EUCTR)	23/04/2008	04/10/2007	Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin	Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patients treated with horse ATG and Ciclosporin	Aquired aplastic anaemia and transfusion dependent non-severe aplastic anaemia MedDRA version: 9.1;Level: LLT;Classification code 10002274;Term: Anemia aplastic	Trade Name: Thymoglobuline Product Name: Thymoglobuline®/Thymoglobulin® Product Code: anti-thymocyte globulin (rabbit) Other descriptive name: GLYCINE Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9% Other descriptive name: Mannitol Trade Name: Neoral Product Name: Ciclosporine INN or Proposed INN: Cyclosporin A Other descriptive name: Ciclosporine	EBMT (European group for Blood and Marrow Transplantation)	NULL	Not Recruiting			Female: yes Male: yes	35	Phase 2	France;Germany;United Kingdom
45	EUCTR2006-006577-25-SE (EUCTR)	25/07/2007	11/06/2007	A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 identical related or unrelated donors. A Nordic multicenter study. - Rapa + FK in stem cell transplantation	A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 identical related or unrelated donors. A Nordic multicenter study. - Rapa + FK in stem cell transplantation	Graft versus host disease prophylaxis in patients receiving stem cell transplantation due to: chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders MedDRA version: 9.1;Level: LLT;Classification code 10018799;Term: GVHD	Trade Name: Rapamune Product Name: Rapamune INN or Proposed INN: SIROLIMUS Other descriptive name: Rapamycin Trade Name: Prograf Product Name: Prograf INN or Proposed INN: TACROLIMUS Other descriptive name: FK-506 Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral INN or Proposed INN: CICLOSPORIN Other descriptive name: CsA Trade Name: Methotrexate Product Name: Methotrexate INN or Proposed INN: METHOTREXATE Other descriptive name: MTX	Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200		Finland;Sweden
46	EUCTR2008-001151-22-IT (EUCTR)	06/06/2007	14/06/2011	ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS. - Alesaa	ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS. - Alesaa	Aplastic anemia and single-lineage bone marrow failure MedDRA version: 13.1;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 13.1;Level: LLT;Classification code 10047350;Term: Very few granulocyte precursors;Classification code 10002967;Term: Aplastic anaemia;Classification code 10001507;Term: Agranulocytosis;System Organ Class: 10005329 - Blood and lymphatic system disorders	Trade Name: MABCAMPATH INN or Proposed INN: Alemtuzumab	UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50		Italy
47	NCT00895739 (ClinicalTrials.gov)	June 2006	7/5/2009	Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure	Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients	Nonmalignant Neoplasm	Biological: alemtuzumab;Drug: cyclosporine	Federico II University	NULL	Recruiting	18 Years	N/A	Both	50	Phase 2	Italy
48	NCT00319878 (ClinicalTrials.gov)	May 2006	28/4/2006	Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia	A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia	Anemia, Aplastic	Drug: Sirolimus;Drug: Cyclosporine	Office of Rare Diseases (ORD)	Rare Diseases Clinical Research Network	Recruiting	21 Years	N/A	Both	52	Phase 1/Phase 2	United States
49	NCT00343785 (ClinicalTrials.gov)	February 2006	22/6/2006	Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant	Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial	Aplastic Anemia	Drug: cyclophosphamide;Biological: anti-thymocyte globulin;Drug: cyclosporine;Procedure: allogeneic bone marrow transplantation;Drug: methotrexate;Genetic: DNA analysis;Other: flow cytometry;Genetic: polymorphism analysis;Other: laboratory biomarker analysis	Fred Hutchinson Cancer Research Center	National Heart, Lung, and Blood Institute (NHLBI)	Completed	N/A	65 Years	All	21	Phase 2	United States;Canada
50	NCT00354419 (ClinicalTrials.gov)	February 2006	19/7/2006	Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant	A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood	Aplastic Anemia	Radiation: total-body irradiation;Drug: cyclophosphamide;Biological: anti-thymocyte globulin;Drug: cyclosporine;Procedure: umbilical cord blood transplantation;Drug: mycophenolate mofetil;Procedure: bone marrow aspiration;Genetic: DNA analysis;Biological: filgrastim	Fred Hutchinson Cancer Research Center	National Cancer Institute (NCI)	Terminated	N/A	40 Years	Both	30	Phase 1	United States
51	NCT00260689 (ClinicalTrials.gov)	November 28, 2005	1/12/2005	Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia	A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab	Immunosuppresion;Thrombocytopenia;Pancytopenia;Neutropenia	Biological: Anti-thymocyte globulin (rabbit);Biological: Anti-thymocyte globulin (horse);Drug: Cyclosporine;Drug: Alemtuzumab	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	N/A	All	136	Phase 2	United States
52	NCT00195624 (ClinicalTrials.gov)	September 15, 2005	16/9/2005	Alemtuzumab to Treat Severe Aplastic Anemia	A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia	Severe Aplastic Anemia, Refractory;Severe Aplastic Anemia, Relapse	Biological: Alemtuzumab (Campath );Drug: Cyclosporine	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	110 Years	All	47	Phase 2	United States
53	NCT00806598 (ClinicalTrials.gov)	May 2005	9/12/2008	Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome	Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome	Myelodysplastic Syndrome;Aplastic Anemia	Drug: Thymoglobulin;Drug: Cyclosporine;Drug: Methylprednisolone;Drug: G-CSF	M.D. Anderson Cancer Center	Genzyme, a Sanofi Company	Completed	15 Years	N/A	All	53	Phase 2	United States
54	NCT01231841 (ClinicalTrials.gov)	March 2005	29/10/2010	Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia	Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)	Aplastic Anemia	Drug: cyclosporine;Biological: anti-thymocyte globulin	The Cleveland Clinic	NULL	Completed	12 Years	N/A	All	20	Phase 2	United States
55	NCT00061360 (ClinicalTrials.gov)	June 26, 2003	23/5/2003	Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia	A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia	Severe Aplastic Anemia	Drug: ATG+Rapamune+cyclosporine;Drug: ATG+cyclosporine	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	110 Years	All	77	Phase 2	United States
56	NCT00533923 (ClinicalTrials.gov)	December 2002	20/9/2007	Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders	Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders	AML;ALL;CLL;Myelodysplastic Syndrome;Non-Hodgkin's Lymphoma;Hodgkin's Lymphoma;Multiple Myeloma;Aplastic Anemia;Myeloproliferative Disorder	Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF	Beth Israel Deaconess Medical Center	Bayer	Completed	N/A	65 Years	Both	25	Phase 2	United States
57	NCT00017654 (ClinicalTrials.gov)	April 2001	6/6/2001	Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia		Graft Versus Host Disease;Aplastic Anemia	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: methylprednisolone;Procedure: Allogeneic Bone Marrow Transplantation	Northwestern Memorial Hospital	NULL	Active, not recruiting	15 Years	55 Years	Both	3	N/A	United States
58	NCT01163942 (ClinicalTrials.gov)	March 2001	14/7/2010	Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)	A RANDOMIZED CONTROLLED STUDY IN NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING ANTITHYMOCYTE GLOBULIN (ATG), CYCLOSPORIN A, WITH OR WITHOUT G-CSF	Aplastic Anaemia	Drug: G-CSF;Drug: Early retreatment with ATG	European Group for Blood and Marrow Transplantation	CHUGAI sanofi-aventis	Terminated	N/A	N/A	Both	205	Phase 3	Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom
59	NCT00005935 (ClinicalTrials.gov)	June 2000	6/7/2000	Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia	A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)	Aplastic Anemia	Drug: Mycophenolate mofetil;Drug: Cyclosporine	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	N/A	N/A	Both	130	Phase 2	United States
60	NCT00001964 (ClinicalTrials.gov)	March 17, 2000	18/1/2000	Combination Therapy of Severe Aplastic Anemia	Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)	Severe Aplastic Anemia	Drug: Cyclosporine A;Drug: ATG;Drug: MMF	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	1 Year	99 Years	All	104	Phase 2	United States
61	NCT00636909 (ClinicalTrials.gov)	July 1999	10/3/2008	Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders	Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders	AML;ALL;CML Chronic Phase, Accelerated Phase, or Blast Crisis;CLL;MDS;RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA;APLASTIC ANEMIA;MULTIPLE MYELOMA;MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)	Drug: Cyclophosphamide;Drug: fludarabine;Drug: cyclosporine;Drug: methotrexate;Biological: G-CSF	Beth Israel Deaconess Medical Center	Amgen	Completed	N/A	65 Years	All	25	Phase 2	NULL
62	NCT00001626 (ClinicalTrials.gov)	June 2, 1997	3/11/1999	Comparing Therapies for the Treatment of Severe Aplastic Anemia	A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia	Severe Aplastic Anemia (SAA)	Drug: antithymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	15 Years	110 Years	All	33	Phase 2	United States
63	NCT00005852 (ClinicalTrials.gov)	June 1996	2/6/2000	Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant	Allogeneic Bone Marrow Transplantation for Marrow Failure States	Chronic Myeloproliferative Disorders;Graft Versus Host Disease;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes	Biological: anti-thymocyte globulin;Biological: filgrastim;Biological: muromonab-CD3;Drug: cyclophosphamide;Drug: cyclosporine;Drug: methylprednisolone;Procedure: allogeneic bone marrow transplantation	H. Lee Moffitt Cancer Center and Research Institute	National Cancer Institute (NCI)	Terminated	15 Years	55 Years	Both		Phase 2	NULL
64	NCT00004323 (ClinicalTrials.gov)	February 1995	18/10/1999	Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia		Aplastic Anemia	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: mesna;Drug: methotrexate;Drug: methylprednisolone	National Center for Research Resources (NCRR)	University of California, Los Angeles	Completed	N/A	55 Years	Both	10	Phase 2	United States

先頭へ

62. 発作性夜間ヘモグロビン尿症

---

臨床試験数 : 292 /  薬物数 : 151 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01760096 (ClinicalTrials.gov)	January 2013	1/1/2013	Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Paroxysmal Nocturnal Hemoglobinuria;Hemoglobinuria;Hemoglobinuria, Paroxysmal;Proteinuria;Urination Disorders;Thrombosis;Bone Marrow Failure;Aplastic Anemia,;Anemia, Hemolytic	Drug: Levamisole+cyclosporin A+Glucocorticoids;Drug: cyclosporin A+Glucocorticoids;Drug: Glucocorticoids	Institute of Hematology & Blood Diseases Hospital	NULL	Active, not recruiting	18 Years	N/A	Both	50	Phase 2	China
2	NCT01642979 (ClinicalTrials.gov)	July 2012	14/7/2012	Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Paroxysmal Nocturnal Hemoglobinuria;Hemoglobinuria;Hemoglobinuria, Paroxysmal;Proteinuria;Urination Disorders;Thrombosis;Bone Marrow Failure;Aplastic Anemia,;Anemia, Hemolytic	Drug: Levamisole+cyclosporin A+Glucocorticoids;Drug: cyclosporin A+Glucocorticoids;Drug: Glucocorticoids	Institute of Hematology & Blood Diseases Hospital	NULL	Active, not recruiting	18 Years	N/A	Both	120	Phase 2	China
3	NCT00397813 (ClinicalTrials.gov)	January 2006	9/11/2006	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial	Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;Chronic Myelomonocytic Leukemia;de Novo Myelodysplastic Syndrome;Essential Thrombocythemia;Myeloproliferative Neoplasm;Paroxysmal Nocturnal Hemoglobinuria;Polycythemia Vera;Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;Primary Myelofibrosis;Refractory Anemia;Refractory Anemia With Excess Blasts;Refractory Anemia With Ring Sideroblasts;Refractory Cytopenia With Multilineage Dysplasia;Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts	Drug: Cyclosporine;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Drug: Mycophenolate Mofetil;Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;Procedure: Peripheral Blood Stem Cell Transplantation;Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center	National Cancer Institute (NCI);National Heart, Lung, and Blood Institute (NHLBI)	Completed	50 Years	75 Years	All	77	Phase 2	United States;Denmark;Germany;Italy

63. 特発性血小板減少性紫斑病

---

臨床試験数 : 391 /  薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200058433	2022-04-11	2022-04-09	Belimumab in combination with cyclosporine for corticosteroid-refractory primary immune thrombocytopenia in adults	Efficacy and safety of belliumab in combination with cyclosporine in adults with persistent or chronic corticosteroid-refractory primary immune thrombocytopenia: a single-arm, open, multicenter clinical study	Primary immune thrombocytopenia	Group 1:belimumab and cyclosporine;	The Second Affiliated Hospital of Kunming Medical University	NULL	Pending			Both	Group 1:37;		China
2	ChiCTR2000040991	2022-03-02	2020-12-16	Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study	Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study	primary immune thrombocytopenia	experimental group:Cyclosporine A combined with eltrombopag;	The First Affiliated Hospital, College of Medicine, Zhejiang University	NULL	Recruiting	18	75	Both	experimental group:28;	Phase 4	China
3	ChiCTR2000030603	2020-05-01	2020-03-08	A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for glucocorticoid-dependent immune thrombocytopenia	A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for glucocorticoid-dependent immune thrombocytopenia	Primary Immune Thrombocytopenia	The short -course glucocorticoid group:treat with glucocorticoid;The eltrombopag group:treat with eltrombopag;The rituximab group:treat with rituximab;Splenectomy group:treat with splenectomy;The azathioprine group:treat with azathioprine;The cyclosporine group:treat with cyclosporine;	The Second Affiliated Hospital of Kunming Medical University	NULL	Recruiting	18	75	Both	The short -course glucocorticoid group:65;The eltrombopag group:65;The rituximab group:65;Splenectomy group:65;The azathioprine group:65;The cyclosporine group:65;	Phase 4	China
4	ChiCTR1900027753	2019-12-01	2019-11-25	Efficacy and safety of cyclosporine and azathioprine in patients with refractory ITP	Efficacy and safety of cyclosporine and azathioprine in patients with refractory ITP	Primary Immune Thrombocytopenia	Group 1:Using cyclosporine A for treatment;Group 2:Using azathioprine for treatment;Control group:Treatment with glucocorticoids;	the Second Affiliated Hospital of Kunming Medical University	NULL	Pending	18	75	Both	Group 1:30;Group 2:30;Control group:30;	N/A	China
5	ChiCTR-OON-17014165	2018-01-01	2017-12-27	A clinical trial to evaluate the efficacy and safety of corticosteroids combined with cyclosporin A in the treatment of primary immune thrombocytopenia	A clinical trial to evaluate the efficacy and safety of corticosteroids combined with cyclosporin A in the treatment of primary immune thrombocytopenia	Immune Thrombocytopenia	one:Corticosteroids;two:Corticosteroids combined with Cyclosporin A ;	Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology	NULL	Recruiting	18	65	Both	one:100;two:100;		China
6	ChiCTR-INR-16009363	2016-10-13	2016-10-10	'Yu Xue Qi Huo' theory based integrated Traditional Chinese and Western Medicine in the diagnosis and treatment of stratified relapsed and refractory primary immune thrombocytopenia	'Yu Xue Qi Huo' theory based integrated Traditional Chinese and Western Medicine in the diagnosis and treatment of stratified relapsed and refractory primary immune thrombocytopenia	Immune Thrombocytopenia	Study Group A:Yangyin Traditional Chinese Medicine: brew the TCM granules in warm water, 1 pack bid p.o. 1 hour after meal for 6 months continuously;Study Group A:Cyclosporin A capsules: 5mg/kg/d p.o., adjusted according to the serum CsA concentration;Control group B:Traditional Chinese Medicine for control group;Control group B:Cyclosporin A capsules: 5mg/kg/d p.o., adjusted according to the serum CsA concentration ;Study Group C:Yangyin Traditional Chinese Medicine: brew the TCM granules in warm water, 1 pack bid p.o. 1 hour after meal for 6 months continuously ;Study Group C:rhTPO: 1ug/kg/d qd for 14 days continuously, ih, until platelet count reaches 100×10^9/L;Control Group D:Traditional Chinese Medicine for control group;Control Group D:rhTPO: 1ug/kg/d qd for 14 days continuously, ih, until platelet count reaches 100×10^9/L ;	Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine	NULL	Recruiting	18	75	Both	Study Group A:55;Study Group A:55;Control group B:55;Control group B:55;Study Group C:45;Study Group C:45;Control Group D:45;Control Group D:45;		China
7	NCT01437384 (ClinicalTrials.gov)	September 2011	19/9/2011	Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.	An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects	Idiopathic Thrombocytopenic Purpura (ITP)	Drug: E5501	Eisai Inc.	NULL	Completed	18 Years	55 Years	Both	36	Phase 1	United States

先頭へ

93. 原発性胆汁性胆管炎

---

臨床試験数 : 298 /  薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04376528 (ClinicalTrials.gov)	June 16, 2021	3/5/2020	Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy	Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy	Hepatitis, Autoimmune;Primary Biliary Cholangitis;Immunosuppression	Drug: Cyclosporin A;Drug: Mycophenolate Mofetil	West China Hospital	NULL	Recruiting	18 Years	70 Years	All	89	Phase 4	China

95. 自己免疫性肝炎

---

臨床試験数 : 52 /  薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04376528 (ClinicalTrials.gov)	June 16, 2021	3/5/2020	Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy	Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy	Hepatitis, Autoimmune;Primary Biliary Cholangitis;Immunosuppression	Drug: Cyclosporin A;Drug: Mycophenolate Mofetil	West China Hospital	NULL	Recruiting	18 Years	70 Years	All	89	Phase 4	China
2	NCT01170351 (ClinicalTrials.gov)	December 2005	24/7/2010	Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis	Comparing Efficacy and Tolerability of Cyclosporine-A vs. Prednisolone for Induction of Remission in Auto-immune Hepatitis	Autoimmune Hepatitis	Drug: Cyclosporine-A	Tehran University of Medical Sciences	NULL	Completed	16 Years	65 Years	All	55	Phase 3	Iran, Islamic Republic of

97. 潰瘍性大腸炎

---

臨床試験数 : 2,630 /  薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05112263 (ClinicalTrials.gov)	January 1, 2023	26/10/2021	Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis	Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis: An Open Label Randomized Study	Ulcerative Colitis	Drug: Tofacitinib;Drug: Cyclosporine	Postgraduate Institute of Medical Education and Research	All India Institute of Medical Sciences, New Delhi	Not yet recruiting	18 Years	65 Years	All	96	N/A	NULL
2	EUCTR2018-003349-41-DE (EUCTR)	30/10/2019	19/12/2018	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Israel;Russian Federation;United Kingdom;France;Hungary;Canada;Poland;Bulgaria;Germany;Belarus;Serbia;United States;Ukraine
3	EUCTR2018-003349-41-FR (EUCTR)	11/07/2019	27/05/2019	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine Product Name: ST-0529 Product Code: FP-CYA-053 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Not Recruiting			Female: yes Male: yes	280	Phase 2	United States;Belarus;Serbia;Spain;Ukraine;Ireland;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Bulgaria;Germany
4	EUCTR2018-003349-41-RO (EUCTR)	01/07/2019	09/05/2022	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine Product Name: ST-0529 Product Code: FP-CYA-053 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Not Recruiting			Female: yes Male: yes	280	Phase 2	United States;Belarus;Serbia;Ukraine;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Canada;Poland;Romania;Bulgaria;Germany
5	EUCTR2018-003349-41-BG (EUCTR)	29/05/2019	27/02/2019	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Spain;Belarus;Serbia;United States;Ukraine;Ireland;Israel;Russian Federation;United Kingdom;Italy;France;Hungary;Canada;Poland;Romania;Bulgaria;Germany
6	EUCTR2018-003349-41-GB (EUCTR)	28/03/2019	21/12/2018	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 2	Belarus;Serbia;United States;Spain;Ukraine;Ireland;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Canada;Poland;Romania;Bulgaria;Germany
7	EUCTR2018-003349-41-PL (EUCTR)	27/02/2019	15/01/2019	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine Product Name: ST-0529 Product Code: FP-CYA-053 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Not Recruiting			Female: yes Male: yes	280	Phase 2	Belarus;Serbia;United States;Ukraine;Israel;Russian Federation;Italy;United Kingdom;France;Hungary;Canada;Poland;Bulgaria;Germany
8	EUCTR2018-003349-41-HU (EUCTR)	19/02/2019	08/01/2019	Clinical trial to evaluate the benefit and safety of ST-0529 in subjects who are suffering from active ulcerative colitis	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis	Active ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: ST-0529 Product Code: FP-CYA-050 INN or Proposed INN: CICLOSPORIN Other descriptive name: cyclosporine	Sublimity Therapeutics (Hold Co) Ltd.	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Belarus;Serbia;United States;Spain;Ukraine;Ireland;Turkey;Israel;Russian Federation;United Kingdom;France;Hungary;Canada;Poland;Belgium;Romania;Bulgaria;Germany
9	JPRN-UMIN000010776	2013/06/01	01/06/2013	An open label randomized controlled trial of tacrolimus versus cyclosporine treatment for severe ulcerative colitis	An open label randomized controlled trial of tacrolimus versus cyclosporine treatment for severe ulcerative colitis - Tacrolimus versus cyclosporine treatment for severe UC	Ulcerative colitis	tacrolimus (Prograf) cyclosporine (Sandimmune)	Chiba University Hospital	NULL	Recruiting	16years-old	65years-old	Male and Female	40	Not selected	Japan
10	EUCTR2008-003169-19-GB (EUCTR)	04/03/2010	17/09/2009	A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis	A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis	Ulcerative colitis MedDRA version: 9.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis	Product Name: CyCol Product Code: CyCol INN or Proposed INN: ciclosporin Other descriptive name: cyclosporine (USAN)	Sigmoid Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Ireland;United Kingdom
11	EUCTR2008-003169-19-IE (EUCTR)	09/11/2009	05/06/2008	A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis	A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis	Ulcerative colitis MedDRA version: 9.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis	Product Name: CyCol INN or Proposed INN: ciclosporin Other descriptive name: cyclosporine (USAN) Product Name: CyCol INN or Proposed INN: ciclosporin Other descriptive name: cyclosporine (USAN)	Sigmoid Pharma Ltd	NULL	Not Recruiting			Female: yes Male: yes	0		United Kingdom;Ireland
12	EUCTR2006-005299-42-BE (EUCTR)	20/05/2008	07/03/2008	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	- Diagnosis of UC according to Lennard-Jones criteria - Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally.- Severe acute flare of UC with a Lichtiger Index score > 10.- Refractoriness to high dose intravenous steroid therapy (= 0.8 mg/kg/d of methylprednisolone or equivalent) given for at least 5 days. MedDRA version: 9.1;Level: LLT;Classification code 10045282;Term: UC	Trade Name: REMICADE INN or Proposed INN: INFLIXIMAB INN or Proposed INN: CICLOSPORIN Other descriptive name: SANDINUM INN or Proposed INN: CICLOSPORIN Other descriptive name: NEORAL Trade Name: CYCLOSPORIN Trade Name: CYCLOSPORIN	GETAID	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		Finland;Belgium;France;Spain
13	EUCTR2006-005299-42-ES (EUCTR)	19/05/2008	03/03/2008	Estudio multicéntrico abierto randomizado que compara ciclosporina e infliximab para el tratamiento de la colitis ulcerosa grave corticorrefractaria.A randomized multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis - CYSIF	Estudio multicéntrico abierto randomizado que compara ciclosporina e infliximab para el tratamiento de la colitis ulcerosa grave corticorrefractaria.A randomized multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis - CYSIF	Brote grave de colitis ulcerosa (Severe flare of ulcerative colitis)	Trade Name: Sandimmum Product Name: ciclosporina Trade Name: Remicade Product Name: infliximab	GETECCU (Grupo Español para el estudio de la enfermedad de Crohn y la colitis ulcerosa)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		Finland;Belgium;France;Spain
14	EUCTR2006-005299-42-FI (EUCTR)	25/02/2008	27/12/2007	A randomized, multicentre, open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitisSatunnaistettu, avoin, vertaileva monikeskustutkimus siklosporiinista ja infliximabista kortikosteroidille reagoimattoman vaikean haavaisen paksusuolitulehduksen hoidossa. - CYSIF STUDY	A randomized, multicentre, open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitisSatunnaistettu, avoin, vertaileva monikeskustutkimus siklosporiinista ja infliximabista kortikosteroidille reagoimattoman vaikean haavaisen paksusuolitulehduksen hoidossa. - CYSIF STUDY	Tutkimuksessa verrataan kortikosteroidihoidolle reagoimattoman haavaisen paksusuolitulehduksen hoitoa käyttämällä suonensisäistä siklosporiinihoitoa 2 mg/kg/vrk 7 vrk:n ajan ja siklosporiini (Sandimmun Neoral) 4 mg/kg/vrk suun kautta tämän jälkeen 3 kk:n ajan verrattuna infliximabi (Remicade) 5 mg/kg iv viikoilla 0, 2 ja 6. MedDRA version: 9.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis	Trade Name: Sandimmun 50 mg/ml, infuusiokonsentraatti INN or Proposed INN: CICLOSPORIN Trade Name: Sandimmun Neoral INN or Proposed INN: CICLOSPORIN Trade Name: Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten INN or Proposed INN: INFLIXIMAB	Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives (G.E.T.A.I.D.)	NULL	Not Recruiting			Female: yes Male: yes	100		France;Finland;Belgium;Spain
15	NCT00542152 (ClinicalTrials.gov)	June 2007	8/10/2007	Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis	A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis	Ulcerative Colitis;Steroid Refractory	Drug: CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	NULL	Completed	18 Years	N/A	Both	115	Phase 4	Belgium;Finland;France;Italy;Spain
16	EUCTR2006-005299-42-FR (EUCTR)	16/05/2007	06/03/2007	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	- Diagnosis of UC according to Lennard-Jones criteria - Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally.- Severe acute flare of UC with a Lichtiger Index score > 10.- Refractoriness to high dose intravenous steroid therapy (= 0.8 mg/kg/d of methylprednisolone or equivalent) given for at least 5 days. MedDRA version: 9.1;Level: LLT;Classification code 10045282;Term: UC	Trade Name: REMICADE INN or Proposed INN: INFLIXIMAB INN or Proposed INN: CICLOSPORIN Other descriptive name: SANDINUM INN or Proposed INN: CICLOSPORIN Other descriptive name: NEORAL Trade Name: CYCLOSPORIN Trade Name: CYCLOSPORIN	GETAID	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		Finland;Belgium;France;Spain

先頭へ

113. 筋ジストロフィー

---

臨床試験数 : 646 /  薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2005-000663-26-AT (EUCTR)	25/04/2005	21/03/2005	Immunsuppressive Therapy in Duchenne Muscular Dystrophy - DMD-CsA	Immunsuppressive Therapy in Duchenne Muscular Dystrophy - DMD-CsA	Duchenne Muscular Dystrophy	Trade Name: Sandimmun Optoral Product Name: Sandimmun Optoral Product Code: 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 Other descriptive name: Cyclosporin A Trade Name: Decortin Product Name: Decortin Product Code: not available Other descriptive name: Prednison	Universitätsklinik Freiburg	NULL	Not Recruiting			Female: no Male: yes	150	Phase 2;Phase 3	Austria

164. 眼皮膚白皮症

---

臨床試験数 : 15 /  薬物数 : 54 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00176865 (ClinicalTrials.gov)	August 2002	12/9/2005	Stem Cell Transplant for Immunologic or Histiocytic Disorders	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism	Hemophagocytic Lymphohistiocytosis;X-Linked Lymphoproliferative Disorders;Chediak-Higashi Syndrome;Griscelli Syndrome;Immunologic Deficiency Syndromes;Langerhans-Cell Histiocytosis	Procedure: Stem Cell Transplant;Drug: Fludarabine;Drug: Melphalan;Drug: Anti-thymocyte globulin (ATG);Drug: Campath 1H;Drug: Cyclosporin A;Drug: Mycophenolate mofetil;Drug: Intravenous immunoglobulin (IVIG)	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	35 Years	All	19	Phase 2	United States
2	NCT00006056 (ClinicalTrials.gov)	March 2000	5/7/2000	Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders		Chediak-Higashi Syndrome;Graft Versus Host Disease;X-Linked Lymphoproliferative Syndrome;Familial Erythrophagocytic Lymphohistiocytosis;Hemophagocytic Lymphohistiocytosis;Virus-Associated Hemophagocytic Syndrome	Drug: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: cyclosporine;Drug: etoposide;Drug: filgrastim;Drug: methotrexate;Procedure: allogeneic hematopoietic stem cell transplantation	Fairview University Medical Center	NULL	Active, not recruiting	N/A	55 Years	Both	40	N/A	United States
3	NCT00006054 (ClinicalTrials.gov)	March 2000	5/7/2000	Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies		Immunologic Deficiency Syndromes;Chediak-Higashi Syndrome;Common Variable Immunodeficiency;Graft Versus Host Disease;X-Linked Lymphoproliferative Syndrome;Familial Erythrophagocytic Lymphohistiocytosis;Hemophagocytic Lymphohistiocytosis;X-linked Agammaglobulinemia;Wiskott-Aldrich Syndrome;Chronic Granulomatous Disease;X-linked Hyper IgM Syndrome;Severe Combined Immunodeficiency;Leukocyte Adhesion Deficiency Syndrome;Virus-Associated Hemophagocytic Syndrome	Drug: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: cyclosporine;Drug: etoposide;Drug: methotrexate;Drug: methylprednisolone;Drug: prednisone;Procedure: Allogeneic Bone Marrow Transplantation	Fairview University Medical Center	NULL	Terminated	N/A	35 Years	Both		N/A	United States

222. 一次性ネフローゼ症候群

---

臨床試験数 : 310 /  薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200059658	2022-05-01	2022-05-05	Establishment and validation of the prediction model of membranous nephropathy	Establishment and validation of the prediction model of membranous nephropathy	membranous nephropathy	Cyclophosphamide based initial treatment:Cyclophosphamide based treatment;Cyclosporine based initial treatment:CNIs based treatment;	People’s Hospital of Guangxi Zhuang Autonomous Region	NULL	Recruiting	14	80	Both	Cyclophosphamide based initial treatment:400;Cyclosporine based initial treatment:400;		China
2	NCT05398653 (ClinicalTrials.gov)	February 24, 2022	26/5/2022	A Clinical Study of MIL62 in Primary Membranous Nephropathy	A Multicenter, Randomized, Controlled, Open Phase Ib/ ? Study Evaluating the Efficacy and Safety of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Primary Membranous Nephropathy.	Primary Membranous Nephropathy	Drug: MIL62;Drug: Cyclosporine	Beijing Mabworks Biotech Co., Ltd.	NULL	Recruiting	18 Years	N/A	All	120	Phase 1/Phase 2	China
3	NCT04743739 (ClinicalTrials.gov)	April 14, 2021	30/1/2021	Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN	A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy	Idiopathic Membranous Nephropathy	Drug: Rituximab;Drug: cyclosporine	Peking Union Medical College Hospital	Beijing Tongren Hospital;Chinese Academy of Medical Sciences, Fuwai Hospital;The Luhe Teaching Hospital of the Capital Medical University;The Seventh Affiliated Hospital, Sun Yat-sen University;First Affiliated Hospital of Xinjiang Medical University;Nanyang Nanshi Hospital of Henan University;Shanghai Fosun Pharmaceutical Development Co, Ltd.	Recruiting	18 Years	80 Years	All	126	Phase 3	China
4	ChiCTR1900021757	2019-03-01	2019-03-08	A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy	The efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial	Idiopathic Membranous Nephropathy	Group 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d);	Nephrology Division, First Hospital Affiliated to Army Medical University	NULL	Recruiting	18	60	Both	Group 1:55;Group 2:55;Group 3:55;Group 4:55;	Phase 4	China
5	NCT03170323 (ClinicalTrials.gov)	July 1, 2018	26/5/2017	Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy	A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy	Idiopathic Membranous Nephropathy	Drug: Mycophenolate Mofetil;Drug: Cyclosporins	Guangdong Provincial People's Hospital	NULL	Recruiting	18 Years	N/A	All	128	Phase 4	China
6	ChiCTR-INR-17012212	2017-07-28	2017-08-01	Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial	Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial	idiopathic membranous nephropathy	1:Cyclosporine;2:cyclosporine combined with sirolimus;	Renal Division, Peking University First Hospital	NULL	Recruiting	18	70	Both	1:35;2:35;		China
7	NCT03180723 (ClinicalTrials.gov)	July 1, 2017	3/6/2017	Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis	Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis	Membranoproliferative Glomerulonephritis	Drug: Rituximab;Drug: Cyclosporin	Assiut University	NULL	Not yet recruiting	18 Years	N/A	All	30	Phase 3	NULL
8	NCT02173106 (ClinicalTrials.gov)	June 2014	23/6/2014	A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy	Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial	Idiopathic Membranous Nephropathy;Proteinuria;Spontaneous Remission;Steroid Nephropathy;Cyclosporin Overdose	Drug: steroid & Cyclosporin	Sun Yat-sen University	NULL	Recruiting	14 Years	75 Years	Both	180	Phase 2	China
9	NCT01180036 (ClinicalTrials.gov)	November 2011	10/8/2010	MEmbranous Nephropathy Trial Of Rituximab	A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)	Idiopathic Membranous Nephropathy	Drug: Rituximab;Drug: Cyclosporine	Mayo Clinic	Columbia University;University of British Columbia;Ohio State University;Stanford University;University of Washington;University of Michigan;University of Alabama at Birmingham;Case Western Reserve University;The Cleveland Clinic;University of Kansas Medical Center;University of Manchester;University Health Network, Toronto;University of Toronto;CHU de Quebec-Universite Laval;Washington University School of Medicine;Florida International University;University of Mississippi Medical Center;NYU Langone Health;Medical College of Wisconsin;University of Arizona;Sunnybrook Health Sciences Centre;Applied Health Research Centre;Fulk Family Foundation	Completed	18 Years	80 Years	All	130	Phase 2/Phase 3	United States;Canada
10	NCT01282073 (ClinicalTrials.gov)	March 2011	19/1/2011	Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy	Glomerulonephritis, Membranous	Drug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin, low dose steroid	Kyungpook National University	Hanmi Pharmaceutical Company Limited	Recruiting	18 Years	N/A	Both	62	Phase 3	Korea, Republic of
11	NCT00977977 (ClinicalTrials.gov)	December 22, 2010	15/9/2009	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy	Nephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous Glomerulonephritis	Drug: Rituximab Infusion;Drug: Oral Cyclosporine	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
12	JPRN-UMIN000000963	2007/10/01	01/01/2010	Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome	Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome - Cyclosporine for MCNS	Minimal change nephrotic syndrome	administration of cyclosporine	Yoshihiko Saito	NULL	Complete: follow-up complete	20years-old	75years-old	Male and Female	30	Not applicable	Japan
13	JPRN-UMIN000000621	2007/03/01	28/02/2007	Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission	Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission - ONTRACK	Minimal change nephrotic syndrome	Prednisolone (+), combination therapy (-) Prednisolone (+), combination therapy (+)	Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	50	Not selected	Japan
14	JPRN-UMIN000004653	2005/01/01	02/12/2010	The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS	The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS - The effects of cyclosporine in onset MCNS	minimal change nephrotic syndrome	cyclosporine A 2-3mg/kg/day	Yokohama city university graduate school of medicine	NULL	Complete: follow-up continuing	16years-old	Not applicable	Male and Female	20	Not applicable	Japan
15	NCT00135811 (ClinicalTrials.gov)	November 2004	24/8/2005	Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)	Focal Segmental Glomerulosclerosis Clinical Trial	Glomerulosclerosis, Focal	Drug: Cyclosporin;Drug: MMF and Dexamethasone	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	The Cleveland Clinic	Completed	2 Years	40 Years	Both	207	Phase 3	United States
16	JPRN-C000000369	2004/04/01	27/03/2006	Multicenter study for combined therapy of prednisolone and cyclosporin in refractory nephrotic syndrome	Multicenter study for combined therapy of prednisolone and cyclosporin in refractory nephrotic syndrome - Combine therapy of prednisolone and cyclosporin in refractory nephrotic syndrome	membranouos nephropathy and focal segmental glomerulosclerosis with primary steroid resistant nephrotic syndrome	CyA-MEPC once a day per os administration at 3mg/kgBW for 48 weeks CyA-MEPC twice a day per os administration at total 3mg/kgBW for 48 weeks	Project team for treatment of refractory nephrotic syndrome	The Progressive Renal Disease Research Projects in the Ministry of Health, Labor and Welfare, Japan	Complete: follow-up complete	16years-old	75years-old	Male and Female	300	Not selected	Japan

先頭へ

274. 骨形成不全症

---

臨床試験数 : 91 /  薬物数 : 101 - (DrugBank : 20) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 48

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00705120 (ClinicalTrials.gov)	November 1995	23/6/2008	Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation	Treatment of Severe (Types II and III) Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation	Osteogenesis Imperfecta	Other: Bone Marrow Cell Transplantation;Radiation: Irradiation, Total Body;Drug: Cyclophosphamide;Drug: Cyclosporin;Procedure: Mesenchymal Stem Cell Transplantation;Drug: Busulfan	St. Jude Children's Research Hospital	NULL	Completed	3 Years	N/A	Both	9	Phase 1	United States

326. 大理石骨病

---

臨床試験数 : 18 /  薬物数 : 43 - (DrugBank : 14) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 82

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01087398 (ClinicalTrials.gov)	September 2009	13/3/2010	Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis	Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis	Osteopetrosis	Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Procedure: Stem Cell Transplantation;Drug: Cyclosporin, Methotrexate (GVHD prophylaxis)	Tehran University of Medical Sciences	NULL	Recruiting	N/A	5 Years	Both	10	Phase 2/Phase 3	Iran, Islamic Republic of

先頭へ